Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters.
Bora Pharmaceuticals announced on Dec. 1, 2020 that it has completed its acquisition of GlaxoSmithKline (GSK)’s Mississauga, Ontario, Canada facility.
Originally announced in March 2020, the acquired facility will be Bora’s first North American manufacturing facility and will serve as its North American headquarters, a company press release said. The new facility will allow Bora to expand its range of dosage forms while it works to supply formulation development and manufacturing services globally.
“Completing the acquisition marks a major step in our expansion into North America, bringing us closer to many of our current and future customers,” said Bobby Sheng, CEO of Bora Pharmaceuticals, in the press release. “The Mississauga site strengthens our existing state-of-the-art manufacturing network, broadening our capabilities and almost doubling our number of talented colleagues, so that we can continue to support the current and future needs of our customers.”
Source: Bora
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.